At least 19 biotechs and pharmas reported earnings last week. Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Illumina Inc. (NASDAQ:ILMN) and Shire plc (LSE:SHP; NASDAQ:SHPG) all gained more than 10% after reporting EPS that beat consensus estimates and raising guidances. Alexion, which added $3.3 billion to its market cap, also announced that FDA granted breakthrough therapy designation for ALXN1101 to treat molybdenum cofactor deficiency (MoCD) Type A, a rare genetic disorder characterized by severe brain damage and rapid death in newborns. The biotech raised its 2013 EPS and revenue guidances to reflect strong sales growth of Soliris eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Shire gained $2.5 billion in market value after raising its 2013 EPS guidance. The specialty biopharma attributed the increase in part to lower operating costs resulting from its ongoing reorganization. In May, new CEO Flemming Ornskov unveiled a plan to consolidate the company's business units into a single pipeline structure while maintaining its commercial units. (A) Fiscal 2Q; Mcap in $M


3Q13 EPS est

3Q13 EPS actual


Growth from 3Q12

10/25 cls

Wk chg

% chg

Mcap chg

10/25 Mcap

AbbVie Inc. (NYSE:ABBV)



Beat by $0.04







3Q13 revenues were $4.7B, up 4% from 3Q12 and above the Street's estimate of $4.5B. AbbVie spun out of Abbott Laboratories (NYSE:ABT) at the start of 2013. Global sales of autoimmune drug Humira adalimumab were up 16% to $2.8B, while sales of cholesterol drugs TriCor fenofibrate and Trilipix fenofibric acid declined by 88% to $39M due to the loss of patent exclusivity. The company raised the low end of its 2013 non-GAAP EPS guidance to $3.11-$3.13 from $3.07-$3.13.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)



Beat by $0.04







3Q13 sales of rare blood disorder drug Soliris eculizumab, which accounted for all of Alexion's revenues, rose 36% to $400.4M from $294.1M in 3Q12. The Street was expecting $395.3M. Alexion raised its 2013 revenue guidance to $1.535-$1.540B from $1.52-$1.53B and non-GAAP EPS guidance to $3.02-$3.04 from $2.97-$3.02.

Amgen Inc. (NASDAQ:AMGN)



Beat by $0.17







3Q13 revenues were $4.7B, beating the Street's estimate of $4.6B and up 10% from $4.3B in 3Q12. 3Q13 sales of cancer drug Xgeva denosumab rose 30% to $261M, while 3Q13 sales of Prolia denosumab for osteoporosis were up 62% to $178M. Sales of autoimmune drug Enbrel etanercept increased 7% to $1.2B. Sales of Epogen epoetin alfa were flat at $491M, while sales of fellow anemia drug Aranesp darbepoetin alfa fell 10% to $449M. Amgen said it now expects full-year EPS of $7.35-$7.45 and 2013 revenues of $18.3-$18.5B. The company previously expected EPS of $7.30-$7.45 and revenues to be at the upper end of $17.8-$18.2B.